The American Business Council has warned authorities that they had better get the matter sorted out or the country will soon face shortages.
It took a year after the initial announcement, but Johnson & Johnson ($JNJ) finally gained European regulatory approval for its $21.3 billion bid to buy Synthes.
In the face of a sluggish economy barely recovering from its historic collapse in 2008, almost all of the companies made a concerted effort to boost their R&D spending during their 2011 fiscal years.
William Weldon really is a piece of work. In January he told analysts the consumer products plant in Fort Washington, PA, would open in 2013.
Johnson & Johnson's manufacturing overhaul has hit some unexpected roadblocks.
The two research powerhouses will conduct a drug-drug interaction study.
Johnson & Johnson's first-quarter sales may have taken a hit, but its prescription drugs business actually grew.
Manufacturing issues that have led to recalls and product shortages continue to be a drag on the earnings of Johnson & Johnson, but the company saw its first quarter profits rise by double digits.
Alex Gorsky's name has surfaced in the U.S. government's Risperdal marketing lawsuit just weeks before he is supposed to step up into the role of CEO at Johnson & Johnson.
Johnson & Johnson is facing more bad news over its metal-on-metal artificial hip implant products, this time in New Zealand and Australia.